Modeyso: patented from NIH-funded research

Pennsylvania State University reported 2 patents on this drug to NIH as inventions made with NIH grant money. Chimerix lists them with the FDA as protecting Modeyso.

Patent reported to NIH as grant-funded

Medicare paid, 2024

—

before rebates

Medicare, 2020–2024

Medicaid paid, 2024

—

before rebates

NIH grants behind the patents

$6.4M

whole-grant totals, not the drug's cost

The public record, link by link

1 · Public money
NIH grant to University of Pennsylvania, $6.4M in all.
2 · Patent
9629842, RE46290, reported to NIH under U54CA105008.
3 · FDA approval
Approved Aug 6, 2025, held by Chimerix (NDA 219876).
4 · Public pays
Not yet in the Medicare or Medicaid spending files, which run to 2024.

The grants

Totals are everything NIH paid on each grant since 1985. A grant usually funded more than this one invention.

Grant	Research	Years	NIH paid
U54CA105008 NCI	Network for Translational Research: Optical Imaging University of Pennsylvania	2003–2007	$6.4M

Grant

Research

Years

NIH paid

U54CA105008

NCI

Network for Translational Research: Optical Imaging

University of Pennsylvania

2003–2007

$6.4M

The patents

Patents the FDA lists for this drug that were also reported to NIH as grant-funded inventions.

US 9629842
Small Molecule TRAIL Gene Induction by Normal and Tumor Cells as an Anticancer Therapy
Reported by Pennsylvania State University
FDA-listed expiry Apr 30, 2032
US RE46290
Small Molecule TRAIL Gene Induction by Normal and Tumor Cells as an Anticancer Therapy
Reported by Pennsylvania State University
FDA-listed expiry Aug 30, 2032

Chimerix's side

Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they often license the patent from the university and pay royalties on sales. Those terms are not public. The FDA's approval records for Modeyso are linked above, and Chimerix's page shows its other drugs on this list. If Chimerix wants to add its account, we will publish it here.

How this is built. Universities and companies that use NIH grants must report the inventions those grants produce to NIH, under the Bayh-Dole Act. NIH publishes the patent numbers and the grants they were reported under. We match those patents to the patents drug makers list with the FDA for each approved drug (the Orange Book), then add what Medicare Part D, Part B and Medicaid paid for each drug. Only patents still listed with the FDA appear, so drugs whose patents have expired drop out, and biologics, which the Orange Book does not cover, are not here yet.

What the numbers mean. "NIH grants" is everything NIH paid out on the grants a patent was reported under, from 1985 on. A grant usually paid for more than the one invention, so it is not the cost of the drug. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Companies also paid for the clinical trials that took these drugs to approval; each drug page links the company's own filings.

Sources: NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent and product files; Medicare Part D Spending by Drug; Medicare Part B Spending by Drug; Medicaid Spending by Drug. Updated 2026-11-05.